Stimulation of in vivo angiogenesis using dual growth factor-loaded crosslinked glycosaminoglycan hydrogels

被引:84
作者
Riley, Celeste M.
Fuegy, Peter W.
Firpo, Matthew A.
Shu, Xiao Zheng
Prestwich, Glenn D.
Peattie, Robert A.
机构
[1] Oregon State Univ, Dept Chem Engn, Corvallis, OR 97331 USA
[2] Univ Utah, Sch Med, Dept Surg, Salt Lake City, UT 84132 USA
[3] Univ Utah, Dept Med Chem, Ctr Therapeut Biomat, Salt Lake City, UT 84108 USA
关键词
angiogenesis; glycosaminoglycans; growth factors; cytokine; vascular endothelial growth factor; angiopoietin-1;
D O I
10.1016/j.biomaterials.2006.08.029
中图分类号
R318 [生物医学工程];
学科分类号
0831 ;
摘要
Crosslinked, chemically modified hyaluronan (HA) hydrogels pre-loaded with two cytokine growth factors, vascular endothelial growth factor (VEGF) and angiopoietin-1 (Ang-1), were employed to elicit new microvessel growth in vivo, in both the presence and absence of heparin (Hp) in the gels. HA hydrogel film samples were surgically implanted in the ear pinnae of mice, and the ears were harvested at 7 or 14 days post-implantation. Analysis of neovascularization showed that each of the treatment groups receiving an implant.. except for HA/Hp at day 14, demonstrated significantly more microvessel density than control ears undergoing surgery but receiving no implant (p < 0.015). Treatment groups receiving either Ang-1 alone, or aqueous co-delivery of both Ang-1 and VEGF, were statistically unchanged with time. In contrast, film delivery of both growth factors produced continuing increases in vascularization from day 7 to day 14 in the absence of Hp, but decreases in its presence. However, presentation of both VEGF and Ang-1 in crosslinked HA gels containing Hp generated intact microvessel beds with well-defined borders. The HA hydrogels containing Ang-1+VEGF produced the greatest angiogenic response of any treatment group tested at day 14 (NI = 7.44 in the absence of Hp and 4.67 in its presence, where NI is a neovascularization index). Even in the presence of Hp, this had 29% greater vessel density than the next largest treatment group receiving HA/Hp + VEGF (NI = 3.61, p = 0.04). New therapeutic approaches for numerous pathologies could be notably enhanced by the localized, sustained angiogenic response produced by release of both VEGF and Ang-1 from crosslinked HA films. (c) 2006 Elsevier Ltd. All rights reserved.
引用
收藏
页码:5935 / 5943
页数:9
相关论文
共 40 条
[1]   Constitutive expression of phVEGF165 after intramuscular gene transfer promotes collateral vessel development in patients with critical limb ischemia [J].
Baumgartner, I ;
Pieczek, A ;
Manor, O ;
Blair, R ;
Kearney, M ;
Walsh, K ;
Isner, JM .
CIRCULATION, 1998, 97 (12) :1114-1123
[2]   Angiogenesis in health and disease [J].
Carmeliet, P .
NATURE MEDICINE, 2003, 9 (06) :653-660
[3]   Development of poly-(D,L-lactide-coglycolide) microsphere formulations containing recombinant human vascular endothelial growth factor to promote local angiogenesis [J].
Cleland, JL ;
Duenas, ET ;
Park, A ;
Daugherty, A ;
Kahn, J ;
Kowalski, J ;
Cuthbertson, A .
JOURNAL OF CONTROLLED RELEASE, 2001, 72 (1-3) :13-24
[4]   Role of vascular endothelial growth factor in Physiologic and Pathologic angiogenesis: Therapeutic implications [J].
Ferrara, N .
SEMINARS IN ONCOLOGY, 2002, 29 (06) :10-14
[5]   The biology of VEGF and its receptors [J].
Ferrara, N ;
Gerber, HP ;
LeCouter, J .
NATURE MEDICINE, 2003, 9 (06) :669-676
[6]  
FORRESTER JV, 1980, IMMUNOLOGY, V40, P435
[7]  
GODSPODAROWICZ D, 1986, J CELL PHYSL, V128, P475
[8]   HYALURONATE INHIBITION OF CELL-PROLIFERATION [J].
GOLDBERG, RL ;
TOOLE, BP .
ARTHRITIS AND RHEUMATISM, 1987, 30 (07) :769-778
[9]   Physiological and pathological angiogenesis in the endocrine system [J].
Góth, MI ;
Hubina, E ;
Raptis, S ;
Nagy, GM ;
Tóth, BE .
MICROSCOPY RESEARCH AND TECHNIQUE, 2003, 60 (01) :98-106
[10]   MECHANOCHEMICAL SWITCHING BETWEEN GROWTH AND DIFFERENTIATION DURING FIBROBLAST GROWTH FACTOR-STIMULATED ANGIOGENESIS INVITRO - ROLE OF EXTRACELLULAR-MATRIX [J].
INGBER, DE ;
FOLKMAN, J .
JOURNAL OF CELL BIOLOGY, 1989, 109 (01) :317-330